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Abstract
BACKGROUND: Lymphoid enhancer factor-1 (lef-1) is overexpressed in B-cell chronic lymphocytic leukemia (CLL)
when compared with normal B cells and transcribes several genes implicated in the pathogenesis of CLL. We there-
fore hypothesize that antagonism of lef-1 might lead to killing of CLL cells. We used two small molecule inhibitors
of Wnt/β -catenin/lef-1 signaling (CGP049090 and PKF115-584) to test our hypothesis. DESIGN AND METHODS: En-
riched CLL cells and healthy B cells were used in this study. Small interfering RNA (siRNA)–mediated knockdown of
lef-1 in primary CLL cells was done using nucleofection, and 50% lethal concentration (LC50) of two small molecules
was assessed using ATP-based cell viability assay. Apoptotic response was investigated in time course experiments
with different apoptotic markers. Specificity of the small molecules was demonstrated by coimmunoprecipitation ex-
periments for the lef-1/β -catenin interaction. In vivo studies were done in JVM-3 subcutaneous xenograft model.
RESULTS: Inhibition of lef-1 by siRNA leads to increased apoptosis of CLL cells and inhibited proliferation of JVM-3 cell
lines. The two small molecule inhibitors (CGP049090 and PKF115-584) efficiently kill CLL cells (LC50 < 1 μM), whereas
normal B cells were not significantly affected. Coimmunoprecipitation showed a selective disruption of β -catenin/
lef-1 interaction. In vivo studies exhibited tumor inhibition of 69% with CGP049090 and 57% with PKF115-584 when
compared with vehicle-treated controls, and the intervention was well tolerated. CONCLUSIONS: We have demon-
strated that targeting lef-1 is a new and selective therapeutic approach in CLL. CGP049090 or PKF115-584 may be
attractive compounds for CLL and other malignancies that deserve further (pre)clinical evaluation.
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Introduction
The progressive accumulation of mature dysfunctional CD5+, CD19+,
and CD23+ B cells due to failed apoptosis is the major pathophysio-
logical feature of B-cell chronic lymphocytic leukemia (CLL) [1].
Whereas previous studies on the apoptotic block in CLL have mainly
focused on the B-cell lymphoma-2 (bcl-2) gene family [2], aberrant wnt
signaling has been implicated in the pathogenesis of CLL as well [3].
The wnt/β -catenin/lef-1 signal transduction pathway has been
found to be activated in many types of cancer [4]. Binding of secreted
wnt protein to its membrane-bound receptor complex, composed of a
member of frizzled receptor ( fzd ) family and the coreceptor LRP 5/6,
leads to inhibition of phosphorylation of β-catenin by glycogen syn-
thase kinase (gsk-3β ). Unphosphorylated β -catenin remains stable,
accumulates in the cytoplasm, and translocates into the nucleus, where
it activates target gene expression through interaction with the tran-
scription factors T-cell factor (tcf ) and lymphoid enhancer factor-1
(lef-1) [4,5].
Abbreviations: lef-1, lymphoid enhancer factor-1; CLL, B-cell chronic lymphocytic
leukemia; TV, tumor volume; IR, inhibitory rate; siRNA, small interfering RNA
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This tcf /lef-1/β -catenin signaling regulates the expression of c-myc,
cyclin D1 [6–8], and many other target genes involved in the regu-
lation of leukemic cell adhesion, B-cell proliferation, and survival [9–
11]. In CLL, the messenger RNA (mRNA) levels of 6 of 18 wnts
(wnt-3, wnt 5b, wnt-6, wnt-14, and wnt-16 ) and fzd-3 were clearly
elevated in CLL compared with those in peripheral blood lympho-
cytes and normal B cells [3]. Lef-1 is a nuclear protein preferentially
expressed in pre–B cells but not in mature B cells [12]. Most interest-
ingly, three independent studies showed that lef-1 was overexpressed
(∼3000-fold) in CLL cells when compared with that in normal B lym-
phocytes [13–15]. A previous study on β-catenin expression in hema-
topoietic cells indicates that normal T lymphocytes do not express
β-catenin, whereas several leukemia/lymphoma cell lines and primary
leukemia cells have an increased expression [9]. Altogether, β-catenin/
lef-1 signaling is active in CLL, which might prevent apoptosis and
thus contribute to the extended life span of CLL cells.
Recently, 7000 purified natural compounds from proprietary and
public collections were screened, and two small molecules, PKF115-
584 and CGP049090, were identified, which specifically inhibit
β -catenin/tcf /lef-1 interaction in the wnt signaling pathway. The po-
tency of these compounds was demonstrated by several in vitro assays
and reporter gene activation [16]. The aim of this study was to de-
termine the role of lef-1 in the survival of CLL cells and whether
knocking down of this potent transcription factor would be of any
functional relevance.
Materials and Methods
Cell Lines and Patient Samples
MEC-1 and JVM-3 cell lines were obtained from the German Col-
lection of Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany) and maintained in RPMI-1640 with 20% fetal bovine se-
rum and penicillin/streptomycin (Biochrom, Berlin, Germany). With
informed consent, peripheral blood was taken from patients with CLL
during routine diagnostic phlebotomy. Samples were collected into
heparinized tubes from patients treated at our institution. B cells in-
cluded in the current study were enriched using RosetteSep (Stem
Cells, Vancouver, Canada). The study was conducted according to
the Declaration of Helsinki, 6th Revision (2008; World Medical Asso-
ciation, Seoul/South Korea) and approved by the local ethics commit-
tee at the University of Cologne (approval no. 04-231).
Small Molecule Inhibitors
CGP049090 andPKF115-584were obtained fromNovartis Pharma-
ceuticals, Inc (Basel, Switzerland). They were dissolved completely in
70% DMSO in a stock concentration of 3.3 mM and stored in aliquots
at −20°C. For in vivo studies, the inhibitors were first dissolved in one
part of ethanol and then mixed in one part Cremophor EL and nine
parts of sterile water.
Small Interfering RNA–Mediated Knockdown of Lef-1 in
Primary CLL Cells
CLL cells (8 × 106), resuspended in 100 μl of Cell line Solution
Kit V (Amaxa, Cologne, Germany) with 0.5 μMof ON-TARGETplus
SMARTpool lef-1 small interfering RNA (siRNA) or ON-TARGETplus
siCONTROL nontargeting pool as negative control (Dharmacon,
Lafayette, CO), were transfected with the Amaxa Nucleofector I de-
vice (program U-013), cultured in six-well plates in complete medium
for 16 hours and then examined for cell viability and lef-1 protein ex-
pression by Western blot analysis.
ATP-Based Cell Viability Assay
Cell lines, primary CLL cells, and rosetted B cells from healthy
volunteers were seeded in 96-well plates at 2 × 105 cells per well
and treated with various concentrations (0.01, 0.1, 1, and 10 μM)
of the inhibitors for 24 hours including vehicle (DMSO) and un-
treated control. Cell viability was measured using CellTiter-Glo Lu-
minescent Cell Viability Assay (Promega, Madison, WI) according to
the manufacturer’s instructions. Results were generated from three
independent experiments.
Annexin V/Propidium Iodide Staining
Detection of apoptosis by flow cytometry (BD FACS Canto, San
Jose, CA) was determined using Annexin V–fluorescein isothiocyanate
(FITC)/propidium iodide (PI) apoptosis detection kit (BD Pharmingen,
San Diego, CA). Annexin/PI–negative cells were used to denote the per-
cent surviving populations of cells.
Quantitative Real-time Polymerase Chain Reaction
Total RNA from 5 × 106 freshly isolated CLL cells was extracted
using the QIAmp RNA Blood mini kit (Qiagen GmbH, Hilden,
Germany) and converted into first-strand complementary DNA using
SuperScript III First-Strand System (Invitrogen, Carlsbad, CA) accord-
ing to manufacturer’s instructions. Transcript levels were quantified
in duplicate by real-time reverse transcription–polymerase chain re-
action (RT-PCR) on the Roche LightCycler system using the primer
sets and reaction were conditions described in Supporting Infor-
mation. The relative mRNA levels were assessed by normalizing the
obtained fluorescence data of the target gene by those of the house-
keeping gene c-abl (ΔΔC t method).
Caspase 3/7 Activation Assay
CLL samples (n = 3) were seeded into 96-well plates at 2 × 105 cells
per well and treated with 5 μM of the inhibitors at various time points
(0, 2, 4, 6, and 8 hours) including vehicle (0.2% DMSO) and negative
control. Caspase activity was determined using Caspase-Glo 3/7 Assay
(Promega) according to the manufacturer’s instructions.
Immunoblot Analysis
Primary CLL samples were incubated with 5 μM of the inhibi-
tors, and the JVM-3 cell lines were incubated with 10 μM of inhibi-
tors for immunoblot analysis. Antibodies targeting human β -catenin,
cyclin D1, β -actin, caspase 8, and PARP-cleaved form were obtained
from BD Biosciences (San Jose, CA). Anti–human c-myc antibody
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
bodies against human bid; caspases 3, 7, and 9; and human lef-1 were
obtained from Cell Signaling Technology (Danvers, MA). Anti–human
dephospho–β -catenin was obtained from Axxora Life Sciences (San
Diego, CA). Mouse IgG1 κ isotype control antibody was obtained
from eBioscience (San Diego, CA). BD ApoBlock Caspase Inhibitor
was obtained from BD Biosciences. Cytochrome c Apoptosis Detection
Kit was obtained from Promocell GmbH (Heidelberg, Germany).
Total cell protein extracts were prepared in mammalian protein
extraction reagent (M-PER; Thermo Scientific, Waltham, MA) with
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complete protease inhibitor cocktail tablets (Roche Diagnostics, Mann-
heim, Germany) by ultrasonication performed on ice. Nuclear and
cytoplasmic fractionation made using nuclear extract kit (Activemotif,
Carlsbad, CA) according to the manufacturer’s instructions. Equivalent
amounts of protein were resolved by NuPAGE 4% to 12% bis-tris gel
(Invitrogen) and transferred to nitrocellulose membranes and immu-
noblotted as previously described [16].
Coimmunoprecipitation
Coimmunoprecipitation was carried out as previously described
[16] with minor modifications. The eluate was subjected to SDS-
PAGE gel electrophoresis and probed for β -catenin and lef-1 by im-
munoblot analysis.
Indirect Immunofluorescence
A total of 5 × 106 primary CLL cells were incubated with 5 μM
PKF115-584 for 3 hours. The cells were washed twice in PBS, fixed
in 4% paraformaldehyde, permeabilized using Intraprep solution
(Beckman Coulter, Krefeld, Germany) and incubated with primary
antibody (lef-1 or isotype control) for 60 minutes. Cells were later in-
cubated with secondary FITC-labeled antibody for 30 minutes. Cells
were applied to ethanol-rinsed microscopic glass slides, air-dried, and
mounted inVectaShield 4′,6-diamidino-2-phenylindole (DAPI)mount-
ing medium (Vector Laboratories, Burlingame, CA). Images were
acquired by fluorescence microscopy (Nikon Eclipse E800; Nikon,
Duesseldorf, Germany) and analyzed using Lucia software (Nikon).
In Vivo Experiments
A CLL-like xenograft model in nude mice was established as pre-
viously described [17]. The mice were monitored for a week for vis-
ible tumor growth, and tumor size was measured using standard
vernier calipers. When the tumor volume (TV) reached a minimum
of ∼100 mm3, the mice were divided into three groups (eight mice per
group) and treated intraperitoneally with 25 mg/kg of CGP049090,
PKF115-584, or the vehicle control every day for 12 doses. The TV
was measured every third day, and mice that reached a maximum TV
of 1000 mm3 were removed from the study and euthanized owing
to ethical reasons. The day of euthanasia owing to the enlarged TV
was considered as a death event for Kaplan-Meier survival analysis.
TV was measured before therapy and every third day after initiation of
therapy. TV was calculated according to the formula: TV = L (mm) ×
W (mm) × H (mm) / 2, where L is the tumor length and W is the
tumor width. The inhibition rate (IR) of tumor growth on the basis of
TV was calculated according to the formula: IR = (l − RVt / RVc) ×
100%, where RVt represents the mean ratio of TV on day n to TV on
day 0 of a treated group and RVc indicates the ration of the control
group. The largest value for IR was designated as IRmax, which indi-
cates the greatest effect of each test inhibitor. The animal experiments
were carried out with prior approval by the local ethics committee at
University of Cologne (approval no. 50.203.2-K17, 17/05).
Statistical Analysis
GraphPad Prism (GraphPad Software, San Diego, CA) was used
for all statistical analysis. Statistical analyses of data were performed
using unpaired Student’s t-test with 2-tailed comparison unless other-
wise indicated. Differences of P < .05 were considered significantly dif-
ferent from the control.
Results
Expression of Lef-1 and β-Catenin in Healthy B and
CLL Cells
To confirm the overexpression of lef-1 in CLL, we performed
quantitative real-time PCR in primary CLL samples (n = 66) and
healthy B cells (n = 7). The relative mRNA expression of lef-1 was
significantly higher in the CLL samples when compared with the
healthy B cells (P = .0041; Mann-Whitney test; Figure 1A). We
could also show significant overexpression of lef-1 and the presence
of dephospho-β-catenin expression in CLL in comparison with healthy
B cells at the protein level. Figure 1B shows the protein expression of
lef-1 and β-catenin in CLL samples (n = 7), healthy B cells (n = 2), and
CLL cell lines JVM-3 and MEC-1. The CLL cell lines MEC-1 and
JVM-3 express moderate levels of lef-1 and active β-catenin. Finally,
lef-1 is predominantly localized in the nucleus along with β-catenin
in primary CLL, indicating constitutive activation of β-catenin/lef-1
signaling in CLL (Figure 1C).
Lef-1 Knockdown Promotes Apoptosis in Primary CLL
Lef-1 knockdown experiments were performed in six primary
CLL samples by nucleofection using SMARTpool siRNA against
lef-1 with appropriate controls, and cell viability was monitored after
16 hours by flow cytometry using Annexin V/PI staining. Cells nucleo-
fected with lef-1 siRNA had a significantly increased rate of apoptosis
when compared with the cells nucleofected with nontargeting siRNA.
The percent Annexin V−/PI− cells (mean ± SE) was 45.0 ± 3.7% in the
control siRNA transfected cells and 32.4 ± 3.6% in lef-1–transfected
cells (P = .031) as shown in Figure 2A. This validates that knockdown
lef-1 promotes apoptosis of CLL cells. Complete silencing of lef-1
was not achievable because of experimental difficulties of CLL viability
after transfection coupled with massive overexpression of lef-1. How-
ever, lef-1 knockdown was determined at the protein level in two rep-
resentative samples by using anti–lef-1 antibody and anti–β -actin
antibody as loading control (Figure W1, A and B).
Lef-1 Knockdown Promotes Growth Inhibition in JVM-3 Cells
Lef-1 knockdown experiments were performed in JVM-3 cell lines
by nucleofection using SMARTpool siRNA against lef-1 with ap-
propriate controls, and changes in protein level were monitored after
48 hours by immunoblot analysis. Knockdown of lef-1 resulted in
growth inhibition in JVM-3 cell lines (Figure 2B). There was down-
regulation not only of lef-1 target genes c-myc and cyclin D1 but also of
poly(ADP-ribose) polymerase (PARP), pro–caspase 3, and proliferating
cell nuclear antigen (PCNA). Marginal reduction of PARP and pro-
caspase 3 was seen, but their cleaved fragments were not detectable,
indicating lack of apoptotic induction. However, the levels of β-catenin
remained stable, indicating that β-catenin expression is independent of
lef-1 expression.
In Vitro Cytotoxicity of CGP049090 and PKF115-584 in
Primary CLL and Healthy B Cells
Because CLL is a highly complex and heterogeneous disease, we
performed ATP-dependent cell survival assays as described in Mate-
rials and methods in 24 different CLL patient samples to illustrate
the distinct in vitro cytotoxic response that these compounds have
with respect to different subsets of CLL. Table W1 shows the patient’s
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individual response (normalized to the vehicle control) to the inhib-
itors with their corresponding percentage cell kill at 1 μM after
24 hours. No correlation was seen between the patient’s responses
and ZAP70/CD38 status, indicating that both inhibitors exert their
effect independent of these clinical subtypes. The 50% lethal concen-
tration (LC50) calculated from 24 CLL patients was 0.89 μM for
CGP049090 and 0.77 μM for PKF115-584 (Figure 3A). The small
molecules did not show significant cytotoxicity in healthy B cells as
seen in the CLL samples. LC50 values in healthy B cells could not
be obtained owing to lack of complete cell kill (Figure 3B). To date,
MEC-1 and JVM-3 are among the few cell lines that can be consid-
ered CLL-like cells. They were originally derived from a patient with
prolymphocytic transformation of CLL. Both cell lines express κ light
chains, surface CD19, and CD23, but both are negative for CD5 and
have a complex karyotype. Both compounds inhibited the survival of
these cells in a dose-dependent manner. The LC50 values were 0.12 μM
for CGP049090 and 0.49 μM for PKF115-584 in MEC-1 cells (Fig-
ure 3C) and 0.42 μM for CGP049090 and 0.93 μM for PKF115-584
in JVM-3 cells (Figure 3D).
CGP049090 and PKF115-584 Induce Apoptotic Cell Death
To assess whether the observed cell death was mediated by apopto-
sis, we investigated caspase activation using a luminescent caspase 3/7
assay and the accumulation of cleaved PARP by immunoblot analysis
on inhibitor treatment in primary CLL cells. Measuring of caspase 3/7
activity at various intervals allowed us to determine the progression of
apoptosis induction by the inhibitors. CLL cells (n = 3) were incu-
bated in the presence or absence of the inhibitors (5 μM) or the vehi-
cle control (0.1% DMSO) for 0, 2, 4, 6, and 8 hours. Both inhibitors
showed a significant induction of caspase 3 and caspase 7 activities over
time as early as 2 hours after treatment compared with the controls
(Figure 4A). These data indicate that cell death induced by the inhib-
itors is mediated by apoptosis.
Figure 1. Activation of β -catenin/lef-1 signaling in CLL. (A) Relative lef-1 mRNA expression levels between primary CLL (n = 66) and
B cells from healthy volunteers (n = 7) were analyzed using quantitative real-time PCR with abl as the reference housekeeping gene
(***P < .0001; Mann-Whitney test). The results are represented in box plots, with the whiskers indicating the maximum and minimum
values of the data sets. (B) Total protein extracts from primary CLL (n= 7), healthy CD 19+ B cells (n= 2), and CLL cell lines were probed
for lef-1, total β -catenin, and dephospho-β -catenin and β -actin as loading control. (C) Nuclear and cytoplasmic extracts from primary CLL
samples (n = 3) indicate that lef-1 is predominantly localized in the nucleus along with β -catenin.
Neoplasia Vol. 12, No. 4, 2010 Inhibition of Lef-1 in CLL Gandhirajan et al. 329
To avoid the heterogeneity seen in primary CLL cells derived from
different donors, the JVM-3 cell line was used as a model system to enu-
merate the apoptotic mechanism involved. Time course experiments
on JVM-3 cells treated with the inhibitors for 6, 12, and 24 hours
and subsequent immunoblot analysis of whole-cell extracts revealed
cleavage of caspases 9, 3, 7, and 8. In addition, there was also a parallel
decrease of antiapoptotic proteins such as Mcl-1 and XIAP on treat-
ment (Figure 4B).
To distinguish from extrinsic and intrinsic apoptotic pathway, cyto-
chrome C exit and bid cleavage were analyzed. Additional time course
experiments between 0 and 6 hours performed in JVM-3 cell line re-
vealed accumulation of cytochrome C in the cytoplasmic fraction,
Figure 3. In vitro cytotoxicity of CGP049090 and PKF115-584. Tumor cell survival in primary CLL cells (n = 24; A), healthy B cells (n = 7;
B), MEC-1 cell line (three independent experiments; C), and JVM-3 cell line (three independent experiments; D) was ascertained by an
ATP-based cell viability assay. Both substances show dose-dependent cytotoxicity in primary CLL cells as well as in the tested cell lines
but not in healthy B cells. Vertical bars, SE.
Figure 2. SiRNA-mediated lef-1 knockdown leads to apoptosis in primary CLL cells and growth inhibition in JVM-3 cell line. Freshly
isolated CLL cells were nontransfected (NT), mock-transfected (no siRNA), transfected with 0.5 μM control nontargeting or lef-1 siRNA
(n = 6), and cultured for 16 hours in complete medium. (A) Cell viability was evaluated by Annexin V/PI staining, and the results from
each patient are presented as the percentage of Annexin V−/PI− cells (*P< .05). (B) SiRNA-mediated lef-1 knockdown was carried out in
JVM-3 cell lines. Forty-eight hours after nucleofection, protein extracts were analyzed for lef-1, c-myc, cyclin D1, β -catenin, PCNA, and
cleaved PARP by immunoblot analysis, with β -actin as the loading control. There was down-regulation of lef-1 target genes along with
PCNA and PARP, indicating growth inhibition of the cell line. These observations were confirmed in two independent experiments.
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which leads to activation of caspase 3 and caspase 8 at 4-hour interval
in cells treated with PKF115-584 and at 2-hour interval in cells treated
with CGP049090. However, complete down-regulation of mcl-1 and
XIAP did not precede cytochrome C release in the cells treated with
inhibitors (Figure W2, A and B).
CGP049090- and PKF115-584-Induced Apoptosis Is
Inhibited by Pan Caspase Inhibitors
We used pan caspase inhibitors to determine 1) whether the apopto-
sis induced by CGP049090 and PKF115-584 is inhibited by pretreat-
ment with ZVAD-FMK and 2) whether the inhibitors of apoptosis
and lef-1 target proteins are downregulated preceding or succeeding
caspase activation. We treated primary CLL cells with 3 μM of in-
hibitors for 16 hours in the presence or absence of 50 μM pan caspase
inhibitor (ZVAD-FMK) with respective vehicle control for 16 hours.
Pretreatment of CLL cells with pan caspase inhibitors leads to inhi-
bition of lef-1, caspase 3, and PARP. Results also indicate that down-
regulation of antiapoptotic proteins (XIAP and Mcl-1) and lef-1 target
genes (c-myc and cyclin D1) were due to initiation of apoptotic events
(Figure 4C).
CGP049090 and PKF115-584 Are Specific Antagonists for
β-catenin/lef-1 Interaction Ex Vivo
Previous studies have pointed out that the above-mentioned inhib-
itors specifically inhibit interaction between β-catenin and members of
the tcf/lef-1 transcription factor family. Because β -catenin is a direct
target of caspase 3 activity, there is a rapid apoptotic loss of β-catenin
on in vitro treatment; hence, we decided to investigate the ability of
these compounds to inhibit β -catenin/lef-1 interaction in whole-cell
protein extracts of primary CLL samples treated with the inhibitors by
coimmunoprecipitation. The immunoprecipitate was immunoblotted
and probed for β-catenin and lef-1. The results indicate that β-catenin/
lef-1 interaction was almost completely inhibited on 16 hours of incu-
bation of whole-cell extracts with 10 μMCGP049090 or PKF115-584
before coimmunoprecipitation. This underlines the efficacy of the com-
pounds to β-catenin/lef-1 inhibition (Figure 5A).
CGP049090- and PKF115-584-Induced Apoptosis Cleave
Lef-1 Target Genes
Because CGP049090 and PKF115-584 inhibit β-catenin/lef-1 sig-
naling, we assessed the expression of lef-1 target proteins, namely lef-1,
c-myc, and cyclin D1, in three different primary CLL cells by immu-
noblot analysis. The cells were treated with 5 μM of the inhibitors for
48 hours, and whole-cell extract was prepared. The levels of β-catenin,
c-myc, cyclin D1, and lef-1 were found to be significantly reduced,
demonstrating the effect of the inhibitors on inducing apoptosis in dif-
ferent CLL cells (Figure 5B).
Lef-1 Overexpression and Intracellular Colocalization with
PKF115-584 in CLL Cells
Of the two inhibitors tested PKF115-584 had substantial auto-
fluorescence properties (Figure W3). Results of indirect immunoflu-
orescence studies revealed a high expression of lef-1 in both the
cytoplasm and the nucleus in primary CLL cells. PKF115-584 had
a strong cytoplasmic localization during apoptosis, implying that the
inhibition occurs in the cytoplasmic level at lef-1 or β -catenin. Fig-
ure 5C shows the independent and merged channels of a CLL cell
treated with PKF115-584 for 3 hours and labeled with FITC lef-1
antibody and nucleus stained in DAPI. The yellow region in the cyto-
plasm of the merged picture represents colocalization of lef-1 and
Figure 4. Apoptotic cell death induced by CGP049090 and PKF115-584. (A) Caspase 3/7 activity was measured using caspase 3/7 lu-
minescent assay at 0, 2, 4, 6, and 8 hours after treatment with 5 μM of CGP049090 or PKF115-584, including the untreated control and
vehicle control in CLL samples (n = 3). Vertical bars, SE. *Significance with P < .05 relative to the vehicle control. These observations
were confirmed in two independent experiments. (B) Time course experiments were performed on JVM-3 cell lines treated with 10 μM
of the inhibitors and protein lysates immunoblotted at 0-, 6-, 12-, and 24-hour intervals. The substances induce cleavage of caspases 8,
9, 3, and 7 and downregulate antiapoptotic proteins mcl-1 and XIAP in a time-dependent fashion. The experiment was repeated twice,
and the results are from duplicate membranes loaded with same amount of protein that was stripped and reprobed several times from
one representative experiment. (C) A representative blot from primary CLL cells treated with 3 μM of the small molecule inhibitors in the
presence or absence of pan caspase inhibitors. Pan caspase inhibitors block the apoptosis induced by CGP049090 and PKF115-584 as
seen by caspase 3 and PARP cleavage. However, down-regulation of lef-1 target proteins (c-myc, cyclin D1, and lef-1) and inhibitors of
apoptosis (mcl-1, XIAP) was a result of caspase activation in CLL cells.
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PKF115-584, suggesting possible inhibition of lef-1 transport into the
nucleus by the inhibitors.
In Vivo Efficacy of CGP049090 and PKF115-584
We determined the in vivo efficacy and systemic tolerance of these
inhibitors in a JVM-3 xenograft model. The in vivo efficacy and sys-
temic tolerance were first determined in a small cohort (n = 4 per group)
of animals that showed a very good efficacy (Figure 6A). Table W2
shows this observation in initial and final TV (mm3) and the tumor
inhibitory rate (IRmax) of each of the inhibitors calculated as described
in Materials and methods. There was a significant cessation of tumor
growth in the mice treated with CGP049090 and PKF115-584. The
experiment was then repeated in a larger cohort (n = 8 per group), and
the tumor growth response was monitored after administration of
12 doses at 25 mg/kg during a period of 30 days after initiation of
therapy. Both the inhibitors were well tolerated in vivo because there
was no toxic lethality in mice of the tested groups. Kaplan-Meier sur-
vival curves reveal that treatment significantly improves median survival
by 12.5 days (P = .003) with CGP049090 (Figure 6B) and 15.5 days
(P = .0023) with PKF115-584 (Figure 6C ). Immunohistochemical
analysis of the tumor sections reveal down-regulation of lef-1 in mice
treated with CGP049090 and PKF115-584 when compared with the
controls (Figure W4). Furthermore, we observed down-regulation of
PCNA and increased PARP cleavage with CGP049090- and PKF115-
584–treated mice when compared with the controls (Figure W5).
Discussion
Our results consistently confirm overexpression and nuclear localiza-
tion of lef-1 in CLL cells, and targeting lef-1/β -catenin complex using
small molecule inhibitors CGP049090 and PKF115-584 resulted in
induction of apoptosis in CLL cells.
Overexpression of bcl-2 and other inhibitors of apoptosis is known
to be hallmark feature in CLL, which leads to the inhibition of apop-
tosis [18]. Here, we report that the overexpression of lef-1 in CLL is
Figure 5. CGP049090 and PKF115-584 specifically inhibit coimmunoprecipitation of β -catenin and lef-1 and downregulate target gene
expression in primary CLL cells. Total cell protein extracts from primary CLL cells were incubated with 10 μMof CGP049090 or PKF115-584
for 16 hours at 4°C and later immunoprecipitated with β -catenin antibody. Immunoprecipitation was probed for lef-1 and β -catenin by
immunoblot analysis. The results reveal reduced precipitation of lef-1 in the lysate incubated with CGP049090 or PKF115-584. Vehicle
control (0.2% DMSO) also served as the positive control for the interaction. Starting extract is denoted as cell lysate (1/30). IgH is the
immunoglobulin heavy chain of the precipitating antibody. This observation was confirmed in three independent experiments (A). Rosetted
B cells isolated from CLL patients (n = 3) were cultured in the presence of 5 μM CGP049090 or PKF115-584, including the vehicle control,
for 48 hours. Whole-cell extracts from these cells were immunoblotted for cyclin D1, c-myc, β -catenin, and lef-1, with β -actin as the loading
control. Inhibitors selectively decrease endogenous β -catenin/lef-1 target genes in primary CLL cells (B). Cellular uptake of PKF115-584 and
colocalization with lef-1. Primary CLL cells were incubated with PKF115-584 for 3 hours and labeled with primary anti–lef-1 antibody fol-
lowed by secondary FITC antibody. The cells were fixed onto the slides and mounted with DAPI mounting medium. Images were captured
in an epifluorescent microscope in DAPI (top left), PKF115-584 (top right), and FITC (bottom left) channels. Overlaying the three channels
shows yellow tinge in the merged image (bottom right), indicating colocalization of lef-1 and PKF115-584 (C).
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another characteristic feature leading to its extended survival. However,
whereas we could not observe a massive accumulation of β -catenin
in CLL, there is a steady detectable pool of both phosphorylated
and dephosphorylated forms of β -catenin. The maintenance of de-
phosphorylated β-catenin is attributed to autocrine and paracrine ac-
tion (microenvironment) of wnt ligands and BCR ligation on the CLL
cells [3,19–21]. Hence, the aberrant activation of wnt signaling in
CLL is in cooperation with massive expression of lef-1 and a steady
pool of dephosphorylated β-catenin.
Lef-1 can activate transcription of several target genes in a β-catenin–
dependent or –independent manner. c-myc and cyclin D1 are target
genes of lef-1, which act in a β -catenin–dependent pathway [6,7],
whereas E2F1 is expressed in a β-catenin–independent pathway [22].
Hence, even in the absence of wnt ligand stimulation, it can be specu-
lated that lef-1 can transcribe context-dependent genes in CLL. SiRNA-
mediated knockdown experiments of lef-1 resulted in an increased
apoptosis in nonproliferative CLL cells. Complete lef-1 knockdown in
primary CLL cells was not achievable owing to spontaneous apoptosis
exhibited by CLL cells in vitro, poor transfection efficiency and viability
after transfection, and substantial expression of lef-1 in CLL cells. We
performed siRNA-mediated lef-1 knockdown experiments in JVM-3
cell line, which resulted in expected down-regulation of lef-1 target
genes (c-myc and cyclin D1) but led to inhibition of cell proliferation
instead of apoptosis. Cleavage of PARP and procaspase 3 are widely ac-
cepted markers of apoptosis, surprisingly, we observed down-regulation
of procaspase 3 and PARP on lef-1 knockdown in JVM-3 cell lines.
Hence, we investigated the levels of PCNA that is expressed in the
nuclei of cells during the DNA synthesis phase of the cell cycle and
considered as a marker for proliferation [23]. There was reduction of
PCNA levels on lef-1 inhibition, leading to proliferative arrest of the
JVM-3 cell line.
Levels of β-catenin remained stable, indicating β -catenin expres-
sion to be independent of lef-1 expression. c-myc, which is a potent
transcription factor by itself, governs the expression of 15% genes of
human genome involved in cell cycle progression, apoptosis, and cel-
lular transformation [24,25], which might lead to significantly shut-
ting down the transcriptional machinery in the CLL cells, leading to
growth arrest. However, cyclin D1 down-regulation must be regarded
as a surrogate for lef-1 inhibition in the context of our investigation,
but no statement can be made about its functional relevance with
regard to CLL. Lef-1 down-regulation has the potential to inhibit
the expression of several target genes in CLL including lef-1 itself be-
cause its lef-1/β -catenin complexes can activate the promoter for full-
length lef-1 under a positive feedback loop [12]. Taken together,
down-regulation of the above crucial proteins underlines the hierar-
chical importance of β -catenin/lef-1 signaling in CLL cells, and inhi-
bition of this activity could be a viable therapeutic strategy.
We used the known lef-1/β -catenin inhibitors CGP049090 and
PKF115-584 to test the therapeutic benefit of lef-1 inhibition in
CLL. Interestingly, both substances induced cell death in CLL cells
and cell lines at the submicromolar levels (LC50 < 1 μM). How-
ever, we observed that both inhibitors show a wide range of % cell
kill (10%-98%) in 24 different patient samples, with a mean cell
kill of approximately 55% at 1 μM (Table W1). Hence, we made
our mechanistic studies in JVM-3 cell line and used concentrations
higher than the LC50 values in primary CLL cells. It has to be noted
that a previous study attempted the same in CLL using the β-catenin
inhibitor R-etodolac, which was unsuccessful owing to its high LC50
Figure 6. In vivo efficacy of CGP049090 and PKF115-584. (A) TV in mice (n = 4 per group) treated with CGP049090 or PKF115-584 after
administration of five doses at 25 mg/kg during a period of 12 days after initiation of therapy. There was a significant cessation of tumor
growth in the mice treated with CGP049090 and PKF115-584. In another experiment, Kaplan-Meier survival plots with mice (n = 8 per
group) treated with CGP049090 (B) or PKF115-584 (C) at 25 mg/kg for 12 doses indicate that both substances increase the median
survival of the treated groups when compared with the control group.
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greater than 250 μM [3]. Remarkably, despite its efficient induction of
cell death in CLL, the healthy B-cell counterparts were significantly
less affected by the inhibitors. Furthermore, these inhibitors do not
affect the healthy peripheral blood mononuclear cells as seen from
the estimated LC50 values of 37.83 and 113.31 μM for PKF115-
584 and CGP049090, respectively, shown previously by our group
[26]. Hence, both these small molecules have the potency to induce
cell death in leukemic cells at the same time sparing the healthy cells.
Because both CGP049090 and PKF115-584 are still lead com-
pounds from a high-throughput screen, there is little evidence on their
mechanism of apoptotic induction. A short time course for caspase 3
and 7 activation in CLL cells incubated with 5 μM of the inhibitors
revealed a rapid onset of caspase 3 and 7 activation by luminescent
assay. Caspase 3 and 7 are executioner caspases that cleave several in-
tracellular protein targets promoting apoptosis [27,28] as evident from
the detection of cleaved PARP [29]. Mechanistic studies carried out in
JVM-3 cell lines indicate activation of intrinsic pathway by cyto-
chrome C release. Previous studies have indicated that Fas (CD95/
APO-1) signaling is defective in CLL [30] and that this system does
not play a crucial role in inducing apoptosis by cytotoxic drugs or radi-
ation and observed that procaspase 8 processing accompanied the acti-
vation of procaspase 3 [31]. We also observed a similar effect where
cleavage of caspase 3 accompanied caspase 8 cleavage on incubation
with the inhibitors as previously described. However, down-regulation
of mcl-1 and XIAP did not precede cytochrome C release as evident
from cytochrome C release assay (Figure W2, A and B) and pan caspase
inhibition (Figure 4C ). Hence, it is evident that the apoptotic response
was mediated by intrinsic pathway and activation of caspase 3 and
7 leading to cleavage of mcl-1 and XIAP, which are known inhibitors
of apoptosis in CLL [32–34].
Coimmunoprecipitation experiments concord to the previous find-
ings that both CGP049090 and PKF115-584 efficiently inhibit lef-1/
β-catenin interaction [16], However, our caspase inhibition experiments
reveal that there is down-regulation of lef-1 in CLL cells and parallel in-
duction of apoptosis, indicating that these small molecules possess both
inhibiting lef-1/β-catenin interaction and antileukemic cytotoxicity.
CGP049090 and PKF115-584 exert their effect within the micro-
molar range and do not significantly affect normal B cells, but it must
be questioned, however, whether the inhibitors possess a toxic poten-
tial on less differentiated and proliferating hematopoietic cells or other
tissues in vivo. We treated a small cohort of nontransplanted mice
with 50 mg/kg bodyweight daily of CGP049090 or PKF115-584
for 14 days, and they did not develop any gross systemic toxicity (data
not shown). This is consistent to a previous study that investigated
pharmacokinetics and metabolism of another compound, calphostin C,
which structurally resembles PKF115-584 [35]. The authors reported
that intraperitoneal administration of 40 mg/kg bodyweight in CD1
mice resulted in therapeutically relevant plasma levels (Cmax = 2.9 μM).
Moreover, no toxic signs or fatalities could be observed in the animals
during a 30-day observation period after administration.
Initial attempts made to test these inhibitors in a transgenic Eμ-
TCL-1 model were highly unsuccessful because of the unpredictable
deaths in both treated and control groups and the extended period
before the TCL-1 transgenic mice developed leukemia. Hence, owing
to a lack of convincing in vivo tumor model for CLL, we carried out
in vivo studies in JVM-3 subcutaneous xenografts. The results of in vivo
experiments indicate that all of the xenograft mice in the treated groups
survived the entire regimen, with a significant tumor inhibition and
extended survival mediated by lef-1 knockdown when compared with
the controls, regardless of the high proliferative rate exhibited by the
EBV-transformed JVM-3 cells. Hence, it can be stated that both in-
hibitors are well tolerated at doses that are effective for CLL cell kill-
ing in vivo.
Conclusions
To conclude, we report that lef-1 is an attractive therapeutic target
for CLL therapy. Both CGP049090 and PKF115-584 are potential
anticancer agents in CLL and other neoplastic malignancies. Further
investigations are warranted to determine the lef-1 transcriptional ac-
tivity in different subsets of CLL and the feasibility of these small
molecules for therapeutic approach in humans.
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Supporting Information
Primer Sets for Real-time PCR
LEF-1 F 5′-GCCACGGACGAGATGATCC-3′
LEF-1 R 5′-TGTCTGGCCACCTCGTGTC-3′







Abl: 95°C for 5 minutes, 45 cycles of 10 seconds at 95°C, 15 sec-
onds at 60°C, and 15 seconds at 72°C.
LEF-1 95°C for 5 minutes, 45 cycles of 10 seconds at 95°C,
15 seconds at 65°C, and 15 seconds at 72°C.
Immunohistochemistry
The tumor sections embedded in paraffin were incubated in three
washes of xylene for 5 minutes each to deparaffinize the section. Later,
the sections were rehydrated with decreasing concentration of ethanol
(100%, 95%, 75%) 10 minutes each. After rinsing the slides in
ddH2O, the slides are placed in antigen unmasking buffer (TE buffer)
and boiled for 20 minutes. After cooling them down for 5 minutes, the
slides are washed in ddH2O and incubated in 3% hydrogen peroxide
for 10 minutes. The sections were then washed in ddH2O and blocked
in 500 μl of blocking solution for 1 hour. After removing the blocking
solution, 500 μl of primary antibody diluted in the antibody diluent to
each is added to the sections and incubated overnight at 4°C in a hu-
midified chamber.
The next day, the sections are rinsed in wash buffer three times for
5 minutes followed by incubation with 500 μl of biotinylated second-
ary antibody, diluted in Tris-buffered Saline Tween-20, and incubated
in room temperature for 1 hour. The slides are washed again three times
for 5 minutes, and 500 μl of avidin-biotin complex (ABC) reagent is
added to the sections and incubated for 1 hour. The sections were
washed in wash buffer thrice, and 200 μl of 3,3′-diaminobenzidine
(DAB) substrate is added to each section and incubated for 20 min-
utes until the appropriate color reaction develops. The sections were
washed in ddH2O, mounted with coverslips, and observed under docu-
mented with the light microscope.
Figure W1. Freshly isolated CLL cells were nontransfected (NT),
mock-transfected (no siRNA), transfected with 0.5 μM control non-
targeting or lef-1 siRNA (n = 6), and cultured for 16 hours in com-
plete medium. (A) Lef-1 expression was analyzed by immunoblot
analysis in total cell extracts from the indicated patient samples,
with anti–β -actin as the loading control. (B) For each of the two
samples, blot lanes corresponding to control nontargeting and
lef-1 siRNA were subjected to densitometric analysis and normal-
ized to β-actin levels. Columns represent the percentage inhibition
of lef-1 induced by lef-1 siRNA compared with control siRNA.
Figure W2. JVM-3 cell lines were incubated with 10 μM of the inhibitors for 0 to 6 hours. Cytoplasmic fractions were made and immuno-
blotted for cytochrome C , bid, cleaved caspase 3, cleaved caspase 8,Mcl-1, and XIAP. There was increased accumulation of cytochromeC
in the cytoplasm in the first 2 hours in both CGP049090- (A) and PKF115-584–treated cells (B). Cleavage fragments of caspase 3 (17 and
19 kDa) and 8 (18 kDa) were seen at 2 hours with CGP049090 and at 4 hours with PKF115-584. There were no significant changes in XIAP
and Mcl-1 before cytochrome C exit.
Table W1. In Vitro Cytotoxicity of B-CLL Samples to CGP049090 and PKF115-584.
Patient ID ZAP70/CD38 Status* Binet Stage† % Cell Kill at 1 μM
CGP049090 PKF115-584
17 NA NA 54 51
18 ZAP70−/CD38− A 45 10
19 ZAP70−/NA NA 64 67
20 ZAP70+/NA NA 53 75
21 ZAP70−/CD38+ B 55 60
22 ZAP70−/CD38− NA 32 74
23 NA/NA NA 73 62
24 ZAP70−/CD38+ B 60 50
25 NA/NA NA 54 44
26 NA/NA NA 50 29
27 ZAP70−/CD38− C 42 38
28 ZAP70+/CD38− A 71 71
29 ZAP70−/CD38− A 31 14
30 ZAP70−/CD38− C 53 58
31 NA/NA B 41 31
32 ZAP70−/CD38− B 40 56
33 ZAP70−/CD38− B 91 88
34 ZAP70−/CD38− A 45 52
35 ZAP70−/CD38+ B 88 88
36 ZAP70−/CD3− A 47 42
37 ZAP70−/CD38+ B 55 56
38 ZAP70−/CD38+ B 70 60
39 ZAP70−/CD3− B 95 98
40 NA/NA A 56 45
Mean ± SE 56.8 ± 4.0 54.9 ± 3.9
*ZAP70 and CD38 expression was determined by flow cytometry. Cells expressing greater than
20% ZAP70 and greater than 30% CD38 were considered positive.
†Patients classified according to Binet staging system, indicating progressiveness of the disease. NA
represents data not available at the time of completion of the study. The percentage (%) cell kill at
1 μM was calculated from the normalized (vehicle control) raw data.
Figure W3. Freshly isolated CLL cells were incubated with 5 μM of
PKF115-584 for 3 hours. The cells were fixed onto the slides and
mounted with DAPI mounting medium. Images were captured in
an epifluorescent microscope in DAPI channel and phycoerythrin
channel. Nucleus (blue) was stainedwith DAPI, whereas autofluores-
cence of PKF115-584 (red) is seen in the phycoerythrin channel lo-
calized in the cytoplasm.
Figure W4. After 12 doses of therapy (25 mg/kg), a representative mouse from each group was killed, and the tumor was used to
generate paraffin-embedded sections and subsequently labeled for LEF-1 by immunohistochemistry (ABC-DAB). The vehicle-treated
mice (control) shows uniform expression of LEF-1 when compared with the sporadic expression seen in mice treated with
CGP049090 and PKF115-584.
Figure W5. After 12 doses of therapy (25 mg/kg), a representative mouse from each group was killed, and the tumor was used to
generate paraffin-embedded sections and subsequently labeled for PCNA (A) as a marker of proliferation and cleaved PARP as marker
for apoptosis (B) by immunohistochemistry (ABC-DAB). There was a decrease in PCNA expression and increased cleaved PARP in mice
treated with CGP049090 and PKF115-584.
Table W2. In Vivo Therapeutic Effect of CGP049090 and PKF115-584.
Group TV (mm3) IRmax (%)
Initial Final
Control 124.5 ± 21.3 875.9 ± 309
CGP049090 100 ± 21.9 218.2 ± 72.7* 69
PKF115-584 105.8 ± 28.9 318.3 ± 120.8* 57
TV after administration of five doses at 25 mg/kg during a period of 12 days after initiation of
therapy. Mean ± SE.
*P < .05. IRmax indicates the greatest effect of the test inhibitor.
